Literature DB >> 1747070

Potential tolerance against bromobenzene-induced acute hepatotoxicity due to prior subchronic exposure.

S Chakrabarti1.   

Abstract

Groups of adult male Sprague-Dawley rats were treated i.p. with 0, 0.3 and 0.5 mmole bromobenzene (BB)/kg per day in corn oil, 5 days a week for 4 weeks. Thereafter, one half of each of these groups was treated i.p. with a single acute toxic dose of 2.5 mmole BB/kg. Urines were then collected for 24 h and the animals were then sacrificed. The hepatotoxicity induced by an acute dose of BB was significantly reduced due to prior subchronic exposure to BB at 0.5 mmol/kg, but not so at 0.3 mmol/kg. These data indicate a potential tolerance against acute hepatotoxicity of BB due to prior subchronic exposure. A significant increase in the urinary excretion of thioethers or mercapturic acids of BB combined with a significant increase in the urinary level of p-bromocatechol due to prior subchronic treatment with 0.5 mmol BB/kg relative to those due to acute treatment alone was observed. Thus enhanced bromobenzene metabolism could partly explain such potential tolerance against its acute hepatotoxicity. Such protection may also be related to certain cellular events which might occur subsequent to metabolic activation of BB.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1747070     DOI: 10.1007/bf02098037

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  10 in total

1.  Serum glutamic pyruvic transaminase in cardiac with hepatic disease.

Authors:  F WROBLEWSKI; J S LADUE
Journal:  Proc Soc Exp Biol Med       Date:  1956-04

2.  A note on the spectrometric assay of glutamic-oxalacetic transaminase in human blood serum.

Authors:  A KARMEN
Journal:  J Clin Invest       Date:  1955-01       Impact factor: 14.808

3.  Pharmacological implications of microsomal enzyme induction.

Authors:  A H Conney
Journal:  Pharmacol Rev       Date:  1967-09       Impact factor: 25.468

4.  Bromobenzene-induced liver necrosis. Protective role of glutathione and evidence for 3,4-bromobenzene oxide as the hepatotoxic metabolite.

Authors:  D J Jollow; J R Mitchell; N Zampaglione; J R Gillette
Journal:  Pharmacology       Date:  1974       Impact factor: 2.547

5.  Role of detoxifying enzymes in bromobenzene-induced liver necrosis.

Authors:  N Zampaglione; D J Jollow; J R Mitchell; B Stripp; M Hamrick; J R Gillette
Journal:  J Pharmacol Exp Ther       Date:  1973-10       Impact factor: 4.030

6.  Centrolobular hepatic necrosis related to covalent binding of metabolites of halogenated aromatic hydrocarbons.

Authors:  W D Reid; G Krishna
Journal:  Exp Mol Pathol       Date:  1973-02       Impact factor: 3.362

7.  Detection and identification of S-methylcysteine in urine of workers exposed to methyl chloride.

Authors:  R van Doorn; P J Borm; C M Leijdekkers; P T Henderson; J Reuvers; T J van Bergen
Journal:  Int Arch Occup Environ Health       Date:  1980       Impact factor: 3.015

8.  Metabolic activation and detoxification of bromobenzene leading to cytotoxicity.

Authors:  S S Lau; G D Abrams; V G Zannoni
Journal:  J Pharmacol Exp Ther       Date:  1980-09       Impact factor: 4.030

9.  Increased activity of certain hepatic drug-metabolizing enzymes due to subchronic exposure to bromobenzene.

Authors:  S Chakrabarti
Journal:  Toxicol Lett       Date:  1984-01       Impact factor: 4.372

10.  Dose-dependent metabolic excretion of bromobenzene and its possible relationship to hepatotoxicity in rats.

Authors:  S Chakrabarti; J Brodeur
Journal:  J Toxicol Environ Health       Date:  1984
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.